成人原发性FSGS的治疗反应率与肾脏结局
该回顾性队列研究纳入14家医疗中心228例接受免疫抑制治疗的活检确诊原发性FSGS成人患者,55%达到缓解但2年复发率高,中位随访4年39%进展至ESKD,无缓解者和基线eGFR<30者ESKD风险最高。
要点
- 接受免疫抑制治疗的FSGS患者仅55%达到缓解,2年复发率高达63%~75%。
- 中位随访4年,39%进展至ESKD,27%死亡。
- 无缓解者ESKD风险是缓解者的2.22倍,基线eGFR<30者风险显著升高。
核心结论
- 约半数FSGS患者经免疫抑制治疗达到缓解,但复发率高,近40%进展至ESKD,无缓解和低基线eGFR者风险最高。
研究设计与样本
- 回顾性队列研究,纳入14家医疗中心2010至2021年接受免疫抑制治疗的228例活检确诊原发性FSGS成人患者。
主要发现
- 228例中55%达到缓解(12%完全缓解,43%部分缓解),2年复发率63%和75%。
- 中位随访4年(IQR 2.0–7.6),88例(39%)进展至ESKD,62例(27%)死亡,其中33例(15%)在ESKD前死亡。
- 无缓解者较缓解者ESKD风险升高(sHR 2.22;95%CI 1.41–3.49)。
- 基线eGFR<30 vs ≥60 ml/min/1.73m²的ESKD风险sHR 4.74(95%CI 2.24–10.05;P<0.001),基线UPCR>3.5 g/g无统计学意义。
- 亚裔/太平洋岛民患者ESKD风险在种族/族裔组中最高(sHR 2.03;95%CI 1.07–3.84)。
关键数值与推荐
- 缓解定义(评估至8个月):完全缓解UPCR<0.3 g/g;部分缓解UPCR较基线下降>50%且介于0.3–3.5 g/g。
- 复发定义:2年内失去缓解。
- 结局指标包括ESKD(透析或移植)和死亡,采用Fine-Gray亚分布风险比模型分析。
临床怎么用
- 对FSGS免疫抑制治疗应密切监测缓解与复发,无缓解者需积极考虑替代或新型疗法。
- 基线eGFR<30 ml/min/1.73m²提示ESKD高风险,应加强肾脏保护与随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
KEY POINTS: Among 228 FSGS patients treated with immunosuppression, only 55% achieved remission with relapse rates of 63% and 74% by 2 years. Over a median follow-up of 4 years, 39% of FSGS treated patients progressed to kidney failure, and a total of 27% died. Nonresponders to immunosuppression had a >2-fold risk of kidney failure compared with responders. BACKGROUND: FSGS has a variable response to immunosuppressive (IS) therapy and high relapse rates. Lack of US Food and Drug Administration–approved therapies underscore the need for real-world evidence to better understand treatment patterns and outcomes. This study aimed to evaluate treatment response, relapse patterns, and kidney outcomes among patients with primary FSGS. METHODS: A retrospective cohort study was performed within 14 medical centers of an integrated health system. Patients (18 years or older) with biopsy-confirmed primary FSGS treated with IS between 2010 and 2021 were included. Treatment response, assessed at up to 8 months, was categorized as complete remission: urine protein-to-creatinine ratio (UPCR) <0.3 g/g, partial remission: UPCR decline >50% from baseline and between 0.3 and 3.5 g/g, and no remission. Relapse was defined as loss of remission within 2 years. Outcomes, including ESKD (treatment with dialysis or transplant) and mortality, were analyzed using Fine-Gray subdistribution hazard ratio (sHR) models. RESULTS: Among 228 patients treated with IS, 55% achieved remission (12% complete remission, 43% partial remission), with relapse rates of 63% and 75% by 2 years. The median follow-up was 4 years (interquartile range, 2.0–7.6), during which 88 (39%) progressed to ESKD. A total of 62 (27%) patients died, with 33 (15%) deaths occurring before reaching ESKD. Nonresponders had a higher risk of ESKD compared with responders (sHR, 2.22; 95% confidence interval [CI], 1.41 to 3.49). Baseline eGFR <30 ml/min per 1.73 m2 was strongly associated with risk of ESKD (sHR for eGFR of <30 versus 60+, 4.74; 95% CI, 2.24 to 10.05; P < 0.001), while baseline proteinuria (UPCR >3.5 g/g) was NS. Asian/Pacific Islander patients exhibited the highest ESKD risk among racial/ethnic groups (sHR, 2.03; 95% CI, 1.07 to 3.84). CONCLUSIONS: Approximately half of FSGS patients achieved remission with IS, but relapse rates were high, and nearly 40% progressed to ESKD. Nonresponders and low baseline eGFR had the highest risk. These findings underscore the need for novel therapies to achieve durable disease control, lower relapse rates, and improve outcomes in FSGS.
引用
- Sim JJ, Munis MA, Lewing B, et al. Treatment Response Rates and Kidney Outcomes among Adults with Primary FSGS. Clin J Am Soc Nephrol. 2025. PMID: 41055958. doi:10.2215/CJN.0000000898
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。